EFG Asset Management North America Corp. Buys 1,347 Shares of Halozyme Therapeutics, Inc. $HALO

EFG Asset Management North America Corp. increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 104,439 shares of the biopharmaceutical company’s stock after buying an additional 1,347 shares during the quarter. EFG Asset Management North America Corp. owned approximately 0.08% of Halozyme Therapeutics worth $5,432,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Caisse DE Depot ET Placement DU Quebec increased its holdings in Halozyme Therapeutics by 154.5% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 910,169 shares of the biopharmaceutical company’s stock valued at $58,078,000 after buying an additional 552,590 shares during the period. LSV Asset Management boosted its stake in shares of Halozyme Therapeutics by 41.9% during the first quarter. LSV Asset Management now owns 895,191 shares of the biopharmaceutical company’s stock valued at $57,122,000 after purchasing an additional 264,130 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in shares of Halozyme Therapeutics by 27.3% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock worth $72,107,000 after purchasing an additional 242,167 shares during the last quarter. MetLife Investment Management LLC raised its position in shares of Halozyme Therapeutics by 136.6% during the first quarter. MetLife Investment Management LLC now owns 343,741 shares of the biopharmaceutical company’s stock worth $21,934,000 after acquiring an additional 198,476 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at $11,636,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Up 2.8%

Shares of NASDAQ:HALO opened at $68.05 on Wednesday. The company has a market capitalization of $7.96 billion, a PE ratio of 15.57, a price-to-earnings-growth ratio of 0.35 and a beta of 1.16. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The business has a fifty day moving average price of $70.95 and a two-hundred day moving average price of $62.67. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.27 EPS. Analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the completion of the transaction, the director directly owned 46,952 shares of the company’s stock, valued at approximately $3,459,423.36. This represents a 7.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at $55,285,726.65. This represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 108,227 shares of company stock valued at $7,779,595. Company insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on HALO shares. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. JMP Securities increased their price target on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, October 21st. Six equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus price target of $75.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.